-
Benzinga Talks With Imprimis Pharmaceuticals' CEO About Earnings, MKO Melt, Drug Pricing And More
Monday, August 22, 2016 - 9:07am | 708Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) owns, markets and dispenses a portfolio of compounded therapeutic in various areas, including ophthalmology, urology, otolaryngology and infectious diseases. Benzinga had the privilege of chatting with the company's CEO, Mark Baum, about its most recent...